Search | IOVS | ARVO Journals

View

Showing 1 – 5 of 5

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Comparison of four commercially available antiglaucoma drugs on the corneal healing process in the ex vivo eye irritation test (EVEIT) model

Laure Chauchat; Claudia Panfil; Hayette Rebika; Norbert Schrage; Camille Guerin

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):690 – F0144. doi:

ARVO Annual Meeting Abstract June 2022

A comparative pharmacokinetics study of 3 Latanoprost eyedrops solutions containing various excipients in an animal model

Hayette Rebika; Laure Chauchat; Thierry Amar; Karen Viaud-Quentric; Camille Guerin

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4166 – F0158. doi:

ARVO Annual Meeting Abstract June 2022

In vitro permeation of Latanoprost eyedrops in a 3D human corneal tissue model

Camille Guerin; Laure Chauchat; Hayette Rebika; Yulia Kaluzhny; Martine Claret

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4165 – F0157. doi:

ARVO Annual Meeting Abstract April 2014

Conjunctival cell viability and apoptosis after one month of treatment with Thealoz® in dry eye subjects

Hayette Rebika; Alberto López-Miguel; Roberto Reinoso; Carmin Martín; Alfredo Corell; Itziar Fernández; Margarita Calonge; Maria-Jesus J. Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5537. doi:

ARVO Annual Meeting Abstract June 2013

Ocular surface in Sjögren’s syndrome

Hayette Rebika; Sihem Lazreg

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):5446. doi:

Advertisement